947 related articles for article (PubMed ID: 27830348)
1. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
[TBL] [Abstract][Full Text] [Related]
2. Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.
Liu LC; Schutte E; Gansevoort RT; van der Meer P; Voors AA
Expert Opin Investig Drugs; 2015; 24(8):1123-35. PubMed ID: 26095025
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
[TBL] [Abstract][Full Text] [Related]
6. When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases.
Kobayashi M; Girerd N; Zannad F
Nephrol Dial Transplant; 2024 Jun; 39(7):1063-1072. PubMed ID: 38192033
[TBL] [Abstract][Full Text] [Related]
7. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
Yang P; Shen W; Chen X; Zhu D; Xu X; Wu T; Xu G; Wu Q
Heart Fail Rev; 2019 Sep; 24(5):637-646. PubMed ID: 31030322
[TBL] [Abstract][Full Text] [Related]
9. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
Kolkhof P; Delbeck M; Kretschmer A; Steinke W; Hartmann E; Bärfacker L; Eitner F; Albrecht-Küpper B; Schäfer S
J Cardiovasc Pharmacol; 2014 Jul; 64(1):69-78. PubMed ID: 24621652
[TBL] [Abstract][Full Text] [Related]
10. The Role of the Mineralocorticoid Receptor and Mineralocorticoid Receptor-Directed Therapies in Heart Failure.
Young MJ; Kanki M; Karthigan N; Konstandopoulos P
Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34050730
[TBL] [Abstract][Full Text] [Related]
11. Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial.
Vaduganathan M; Claggett BL; Lam CSP; Pitt B; Senni M; Shah SJ; Voors AA; Zannad F; Desai AS; Jhund PS; Viswanathan P; Bomfim Wirtz A; Schloemer P; Lay-Flurrie J; McMurray JJV; Solomon SD
Eur J Heart Fail; 2024 Jun; 26(6):1324-1333. PubMed ID: 38742248
[TBL] [Abstract][Full Text] [Related]
12. Cardiorenal Benefits of Finerenone in Different Races and Kidney Function in Patients with Chronic Kidney Disease.
Li P; Cui Y; Xu X; Dong J; Liao L
Cardiorenal Med; 2024; 14(1):227-234. PubMed ID: 38537621
[TBL] [Abstract][Full Text] [Related]
13. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
Agarwal R; Kolkhof P; Bakris G; Bauersachs J; Haller H; Wada T; Zannad F
Eur Heart J; 2021 Jan; 42(2):152-161. PubMed ID: 33099609
[TBL] [Abstract][Full Text] [Related]
14. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials.
Pamporis K; Karakasis P; Sagris M; Zarifis I; Bougioukas KI; Pagkalidou E; Milaras N; Samaras A; Theofilis P; Fragakis N; Tousoulis D; Xanthos T; Giannakoulas G
Curr Probl Cardiol; 2024 Jul; 49(7):102615. PubMed ID: 38692445
[TBL] [Abstract][Full Text] [Related]
15. Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction.
Lima-Posada I; Stephan Y; Soulié M; Palacios-Ramirez R; Bonnard B; Nicol L; Kolkhof P; Jaisser F; Mulder P
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768859
[TBL] [Abstract][Full Text] [Related]
16. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity.
Grune J; Beyhoff N; Smeir E; Chudek R; Blumrich A; Ban Z; Brix S; Betz IR; Schupp M; Foryst-Ludwig A; Klopfleisch R; Stawowy P; Houtman R; Kolkhof P; Kintscher U
Hypertension; 2018 Apr; 71(4):599-608. PubMed ID: 29437893
[TBL] [Abstract][Full Text] [Related]
17. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
19. Non-steroidal mineralocorticoid receptor antagonists and cardiorenal outcomes in chronic kidney disease.
Lo KB; Rangaswami J; Vaduganathan M
Nephrol Dial Transplant; 2023 Mar; 38(4):845-854. PubMed ID: 36472546
[TBL] [Abstract][Full Text] [Related]
20. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis.
Pei H; Wang W; Zhao D; Wang L; Su GH; Zhao Z
Medicine (Baltimore); 2018 Apr; 97(16):e0254. PubMed ID: 29668577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
